Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis-Reference-Cited by-同舟云学术

Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis

Published:2015-03-15 Issue:4 Volume:97 Page:419-427
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Ferslew BC¹,Johnston CK¹,Tsakalozou E¹,Bridges AS²,Paine MF¹,Jia W³,Stewart PW⁴,Barritt AS⁵,Brouwer KLR¹

Affiliation:

1. Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy; University of North Carolina at Chapel Hill; Chapel Hill North Carolina USA

2. Department of Pathology, UNC School of Medicine; University of North Carolina at Chapel Hill; Chapel Hill North Carolina USA

3. Metabolomics Shared Resource; University of Hawaii Cancer Center; Honolulu Hawaii USA

4. Department of Biostatistics, UNC Gillings School of Global Public Health; University of North Carolina at Chapel Hill; Chapel Hill North Carolina USA

5. Division of Gastroenterology and Hepatology, UNC School of Medicine; University of North Carolina at Chapel Hill; Chapel Hill North Carolina USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference48 articles.

1. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology;Chalasani;Gastroenterology,2012

2. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity;Browning;Hepatology,2004

3. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study;Williams;Gastroenterology,2011

4. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial;Torres;Hepatology,2011

5. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels;Tikkanen;Int. J. Cardiol,2013

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nonalcoholic steatohepatitis increases plasma retention of sorafenib-glucuronide in a mouse model by altering hepatocyte hopping;Acta Pharmaceutica Sinica B;2024-09

2. Inflammatory liver diseases and susceptibility to sepsis;Clinical Science;2024-04

3. Impact of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) on the expression and function of hepatobiliary transporters: A comprehensive mechanistic review;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-03

4. Impact of liver diseases and pharmacological interactions on the transportome involved in hepatic drug disposition;Biochemical Pharmacology;2024-03

5. Physiologically Based Pharmacokinetic (PBPK) Model Predictions of Disease Mediated Changes in Drug Disposition in Patients with Nonalcoholic Fatty Liver Disease (NAFLD);Pharmaceutical Research;2024-02-13